ライフサイエンスコーパス: severe pain

1 rious adverse events (primarily bleeding and severe pain).

2 0 to 10, with higher scores indicating more severe pain).

3 e seen in 6 patients; 8 patients experienced severe pain.

4 10-point scale, with 10 indicating the most severe pain.

5 the choice for the treatment of moderate to severe pain.

6 ugs (NSAIDs) in the treatment of moderate to severe pain.

7 resent a new therapeutic approach to control severe pain.

8 e patients reported experiencing moderate to severe pain.

9 terminally ill patients reported moderate or severe pain.

10 ts had no body pain; 38% had moderate and 4% severe pain.

11 re were 2554 visits; 60% of the patients had severe pain.

12 algesics are widely used in the treatment of severe pain.

13 t supplies of opioids to treat patients with severe pain.

14 algesics; 41% of patients reporting pain had severe pain.

15 mplained of shortness of breath, chills, and severe pain.

16 t and most potent drugs for the treatment of severe pain.

17 mainstay analgesics for treating moderate to severe pain.

18 trical shocks can damage the heart and cause severe pain.

19 s is an attractive alternative treatment for severe pain.

20 tients with Parkinson's disease and chronic, severe pain.

21 pain, 10.3% had moderate pain, and 13.2% had severe pain.

22 ids for moderate pain and strong opioids for severe pain.

23 n clinical trials for the treatment of acute severe pain.

24 analgesics for the treatment of moderate to severe pain.

25 , causes debilitating joint inflammation and severe pain.

26 reported intermediate pain, and 12% reported severe pain.

27 se with moderate pain, and 67% of those with severe pain.

28 and presented with similar symptoms, such as severe pain.

29 associated with receiving OPs for those with severe pain.

30 mong the most used clinical drugs to relieve severe pain.

31 : 1.01-14.9) were associated with persistent severe pain.

32 arter were aggressive, mainly verbally, with severe pain.

33 Sickle cell disease causes severe pain.

34 Opioids are the gold-standard treatment for severe pain.

35 rized in most kindreds by early-age onset of severe pain.

36 More than 60% of Latinos reported severe pain.

37 potent analgesic drugs for the treatment of severe pain.

38 natives for the pharmacological treatment of severe pain.

39 A score of >or=7 was defined as severe pain.

40 erized by loss of feeling in extremities and severe pain.

41 d after onset of a migraine with moderate to severe pain.

42 verbal rating scale, from "no pain" to "very severe pain."

43 More specifically, for those with severe pain, 41% filled an OP within 7 days of assessmen

44 .4%, P < .001), self-reported pain (moderate/severe pain, 41.1% vs 24.2%, P = .003), burning/stinging

45 Among those with chronic severe pain, 65% of MMTP patients and 48% of inpatients

46 ced cancer who were experiencing moderate-to-severe pain; 90% were enrolled in hospice.

47 ar old male child presented to casualty with severe pain abdomen since 1 day.

48 ufficient medications to treat patients with severe pain adequately.

49 a well-recognized problem, with moderate to severe pain affecting 15% to 20% of women at 1 year from

50 who have an operation experience moderate to severe pain after surgery.

51 roblem in lactating women that may result in severe pain and abrupt termination of breastfeeding, the

52 substantial morbidity caused by moderate to severe pain and by spinal cord compression.

53 Persistent severe pain and faecal urgency has been found in a distu

54 ndergoing investigation for the treatment of severe pain and HIV, respectively.

55 of patients suffer from MBD associated with severe pain and increased mortality.

56 icial sources as tanning lamps can result in severe pain and inflammation in the cornea.

57 als such as ammonia (smelling salts) elicits severe pain and inflammation through unknown mechanisms.

58 Severe pain and osteoarthritis predict regular use of CA

59 to bone to form osteolytic lesions, causing severe pain and pathological fracture.

60 ave reported a high incidence of moderate to severe pain and poor analgesia in intensive care units a

61 n the relationship between moderate and more severe pain and prescription opioid use disorders in the

62 Patients with unstable SCFE are in severe pain and unable to bear weight.

63 performed among adults with moderate or more severe pain and with nonmedical opioid use at wave 1.

64 is characterized by a more acute onset, more severe pain, and a rapid response to systemic corticoste

65 IV Parkinson's disease, at least one type of severe pain, and an average 24-h pain score of at least

66 ng to periapical inflammation, bone erosion, severe pain, and tooth loss.

67 least 88% of cancer deaths with moderate to severe pain are untreated.

68 ith a mean of 9 and 28 (71%) described their severe pain as excruciating.

69 es that were sufficient to treat patients in severe pain, as compared with 72 percent of pharmacies i

70 rapid initiation of opioids for treatment of severe pain associated with a vasoocclusive crisis, and

71 sics are traditionally the treatment for the severe pain associated with this disease.

72 Children who had more severe pain at baseline in both groups (P = .0065) had w

73 For patients with moderate-to-severe pain at baseline, the rate of response was signif

74 ients with prodromal symptoms or moderate or severe pain at presentation were also more likely to exp

75 Severe pain at sites of known tumor was dose limiting at

76 al rating scale (score 0-5; 0 = no pain, 5 = severe pain) before surgery and 6 weeks postoperatively.

77 nonsurgical palliation reported moderate to severe pain beyond the third month of treatment.

78 Among those with severe pain, black patients were less likely to receive

79 eptor (MOR) agonists are often used to treat severe pain but can result in adverse side effects.

80 inctive rare condition characterized by less severe pain but marked autonomic activation during attac

81 Opioids remain the mainstay of treatment for severe pain, but the associated hyperalgesia and toleran

82 and dependence among adults with moderate to severe pain, careful monitoring and consideration of non

83 st widely prescribed therapy for moderate to severe pain clinically, they have been noted to alter mi

84 MOR agonist prescribed for the treatment of severe pain conditions that has addictive properties.

85 Severe pain creates fatigue, impairs concentration, comp

86 a highly variable phenotype characterized by severe pain crises, acute clinical events, and early mor

87 Prevalence of chronic severe pain, defined as pain that persisted for more tha

88 The clinical management of severe pain depends heavily on opioids acting through mu

89 The prevalence of moderate or severe pain did not change among all decedents or in any

90 ssociated with fewer days of severe and very severe pain (difference of -0.22 days; 95% CI, -0.41 to

91 ded voltage-gated Na(+) channel NaV1.9 cause severe pain disorders ranging from neuropathic pain to c

92 ing stable opioid therapy and experiencing a severe pain episode were randomly assigned to either 100

93 apy to become the standard for management of severe pain events in children and adults with SCD requi

94 elf-limited toxicities of 3F8 treatment were severe pain, fever, urticaria, and reversible decreases

95 ading to inflammation, bone destruction, and severe pain for the patient.

96 and intervention for a middle-aged man with severe pain from spinal metastases to discuss 4 key ques

97 rol was more likely among patients with more severe pain, greater anxiety, depression, and alteration

98 The reduction in severe pain (> 5 on a scale of 1 to 10) from 27.0% to 19

99 trial, patients with one CAF and moderate-to-severe pain (>/=50 mm on a 100 mm visual analog scale [V

100 extremities and axial pain with moderate or severe pain in at least one of the three regions.

101 f a tertiary care centre with a complaint of severe pain in both hip joints.

102 orphine the opioid of choice for moderate to severe pain in cancer?

103 However, these drugs can cause unexplained severe pain in patients, often referred to as calcineuri

104 Current treatment of moderate to severe pain in SCD is mostly reliant upon opioids; howev

105 tance): pain in the back or lower extremity, severe pain in the operated hip, poor mental health, mor

106 ed in diabetic patients with sudden onset of severe pain in the thigh or calf muscles who have MR ima

107 closely matches the incidence of moderate to severe pain in trauma patients, indicating appropriate p

108 eat tail-flick test, an assay of moderate to severe pain in which opioids are effective.

109 ts millions of women and is characterized by severe pain, increased frequency of micturition, and chr

110 Among those with chronic severe pain, inpatients were significantly more likely t

111 ht be a useful pain-regulation strategy when severe pain is expected.

112 Chronic severe pain is prevalent among patients in substance abu

113 One patient had severe pain lasting 2 weeks, followed by milder pain for

114 Limited options for treating moderate-severe pain led to an overreliance on opioids and the cu

115 ndards were developed for minor pain (<30%), severe pain (<3%), vasovagal hypotension (<3%), signific

116 Opioids remain the mainstay of severe pain management in patients with cancer.

117 d pain (median 14 months, 13-NA) or moderate-severe pain (median 11 months, 9-13).

118 Four in 10 patients had severe pain most of the time.

119 strong opioids in survivors with moderate to severe pain, most pain problems in cancer survivors will

120 all Ultraflex; n=6), food obstruction (n=3), severe pain (n=2), esophageal rupture (n=2), hemorrhage

121 Severe pain/narcotic dependency, tumor size larger than

122 reported extremely severe pain or moderately severe pain occurring at least half of the time, and nea

123 tis (odds ratio, 5.6 [95% CI, 1.9 to 16.8]), severe pain (odds ratio, 2.5 [CI, 1.4 to 4.8]), and a co

124 intestinal tract or abdominal viscera causes severe pain often with vomiting due to oedematous bowel

125 minally ill patients experienced moderate to severe pain, only 30% of them wanted additional pain tre

126 Patients might have severe pain or be asymptomatic.

127 Nearly 15% reported extremely severe pain or moderately severe pain occurring at least

128 Moderate to severe pain or stiffness was reported in 55% of patients

129 stablished on ART, and reporting moderate-to-severe pain or symptoms.

130 or scale (VDS) ("none", "mild", "moderate", "severe" pain) or a 100-mm visual analog scale (VAS) anch

131 ular inflammation without prominent redness, severe pain, or hypopyon.

132 or a child with sciatic nerve zoster who had severe pain over the lower back 6 days before appearance

133 eater impairment of HRQOL compared with less severe pain (P < 0.0001).

134 rer general function (HAQ; P < 0.0001), more severe pain (P = 0.002), greater fatigue (P = 0.0005), g

135 ks, fewer NCPB patients reported moderate or severe pain (pain intensity rating of > or =5/10) vs opi

136 or chemotherapy had failed and who reported severe pain (pain score > or = 4 [scale of 0-10]) over a

137 ain management, pain severity, time spent in severe pain, pain interference, and satisfaction.

138 nduced neuropathy is characterized by acute, severe pain, peripheral nerve degeneration, and autonomi

139 ar efficacy in reducing early, moderate, and severe pain-related responses, suggesting that TRPV1 may

140 ent of analgesic agents for the treatment of severe pain requires the identification of compounds tha

141 gross hematuria, allograft pancreatitis, and severe pain requiring overnight hospitalization.

142 ue scale, with higher scores indicating more severe pain), return emergency department visits, hospit

143 4%, moderate pain (scores 5-7) in 34.5%, and severe pain (scores 8-10) in 7.1% of patients.

144 pain and less likely to receive opioids for severe pain, suggesting a different threshold for treatm

145 ache," "hurt," and "discomfort," may reflect severe pain symptoms, disability, and more serious joint

146 Inherited erythromelalgia (IEM), a severe pain syndrome characterized by episodes of intens

147 Cluster headache, one of the most severe pain syndromes in human beings, is usually descri

148 Cluster headache, one of the most severe pain syndromes in humans, is usually described as

149 can suffer breakthrough pain (BTP), episodic severe pain that "breaks through" the medication.

150 iring joint replacement and with moderate-to-severe pain that had been inadequately controlled by wea

151 fects to analgesic treatment for moderate to severe pain that interfered with functional activity; ho

152 ximately 5% to 10% of survivors have chronic severe pain that interferes with functioning.

153 arge proportion of patients have moderate to severe pain that needs treatment with opioid analgesics.

154 More severe pain was associated with greater impairment of HR

155 Chronic severe pain was experienced by 37% of MMTP patients (95%

156 Severe pain was reported by 4 patients in the TEP group

157 patients with OA of the knee and moderate-to-severe pain were enrolled in a randomized, double-blind,

158 Patients with moderate or severe pain were less likely to die at home (OR, 0.56; 9

159 Those with severe pain were more likely than those with lower level

160 atients who required therapy for moderate to severe pain were randomized to CR oxycodone every 12 hou

161 0 to 100, with higher scores indicating more severe pain) were similar in the placebo, lavage, and de

162 DRG neuron hyperexcitability associated with severe pain, whereas loss of the Na(v)1.7 channel in pat

163 nitially reported pain on most days and more severe pain while walking (P < 0.05).

164 arly in patients with moderate to moderately severe pain who do not respond to or who cannot tolerate

165 represent a new approach to the treatment of severe pain with an improved safety profile.

166 ing severe unrelenting pain alone (group 1), severe pain with intermittent acute exacerbations (group

167 All subjects developed severe pain within 8 weeks of intensive glucose control.